Efficacy of TAS-102 Continues to Hold Up in Metastatic CRC and Gastric Cancers
Howard S. Hochester, MD, discusses findings from the pooled safety analysis of TAS-102 in previously treated patients with colorectal cancer and gastric/gastroesophageal junction adenocarcinoma.